B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview

• B-Cell Maturation Antigen (BCMA) Targeted Therapies market size has reached to $15.09 billion in 2025 • Expected to grow to $44.29 billion in 2030 at a compound annual growth rate (CAGR) of 24% • Growth Driver: Rising Incidence Of Multiple Myeloma • Market Trend: Innovations in CAR-T Cell Treatment for Multiple Myeloma • North America was the largest region in 2025.

What Is Covered Under B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

B-cell maturation antigen (BCMA) targeted therapies refer to a class of treatments designed to specifically target BCMA, a protein expressed on the surface of mature B-cells and plasma cells. BCMA is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in B-cell development, survival, and differentiation into plasma cells. BCMA-targeted therapies represent a significant advancement in the treatment of multiple myeloma, offering effective options for patients with relapsed or refractory disease. The main types of products for B-cell maturation antigen (BCMA) targeted therapies include antibody-drug conjugates (ADCs), chimeric antigen receptor T (CAR-T) cell therapy, and bispecific antibodies. Antibody drug conjugates (ADCs) are targeted therapies that link a cancer-specific antibody to a cytotoxic drug, enabling precise destruction of cancer cells while minimizing damage to healthy tissue. Main types of indication type are acute lymphoblastic leukemia, and multiple myeloma and used by various end users including hospitals, specialty clinics, and home care settings.

What Is The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Forecast?

The b-cell maturation antigen (bcma) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $44.29 billion in 2030 at a compound annual growth rate (CAGR) of 24.0%. The growth in the forecast period can be attributed to increasing approvals of next-generation bcma therapies, rising demand for off-the-shelf immunotherapies, expansion of combination treatment strategies, growing focus on durable remission outcomes, increasing use of ai-driven patient stratification. Major trends in the forecast period include increasing adoption of car-t cell therapies, rising development of bispecific antibody platforms, growing use of bcma-targeted adcs, expansion of personalized immunotherapy regimens, enhanced focus on relapsed and refractory myeloma care.

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segmentation

1) By Product Type: Antibody Drug Conjugates, Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, Bispecific Antibodies 2) By Indication Type: Multiple Myeloma, Plasma Cell Leukemia 3) By End User: Hospitals, Specialty Clinics Subsegments: 1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates), Linker-Payload Technology-Based BCMA ADCs 2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous), Allogeneic BCMA CAR-T Cells 3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies, BCMA x CD28 Bispecific Antibodies

What Is The Driver Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

The rising incidence of multiple myeloma is expected to propel the growth of the b-cell maturation antigen (BCMA) targeted therapies market going forward. Multiple myeloma is a type of cancer that primarily affects plasma cells, which are a crucial component of the immune system responsible for producing antibodies. The increasing incidence of multiple myeloma is attributed to several factors, including an aging global population, improved diagnostic capabilities, and variations in healthcare access. B-cell maturation antigen (BCMA) targeted therapies are crucial in treating multiple myeloma by targeting and eliminating malignant plasma cells that express BCMA, offering a promising approach for more effective and targeted treatment. For instance, in August 2024, according to the American Cancer Society, a US-based professional organization, in 2024, approximately 35,780 new cases of multiple myeloma were diagnosed in the United States, with 19,520 cases in men and 16,260 cases in women. Additionally, about 12,540 deaths are anticipated, including 7,020 in men and 5,520 in women. Therefore, the rising incidence of multiple myeloma is driving growth in the b-cell maturation antigen (BCMA) targeted therapies industry.

Key Players In The Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

Major companies operating in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche, Ichnos Sciences

Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends and Insights

Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are focusing on developing innovative treatments such as CAR-T cell therapy to enhance the efficacy and precision of targeting cancer cells. CAR-T cell therapy is a type of immunotherapy that involves modifying a patient's T cells to express chimeric antigen receptors (CARs) to target and kill cancer cells. For instance, in April 2024, Johnson & Johnson, a US-based pharmaceutical industry company, received U.S. Food and Drug Administration (FDA) approval for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell immunotherapy for treating adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy and are refractory to lenalidomide.

What Are Latest Mergers And Acquisitions In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical industry company, acquired Gracell Biotechnologies Inc. for approximately $1.2 billion. With this acquisition, AstraZeneca aims to enhance its cell therapy portfolio by integrating Gracell's FasTCAR-enabled GC012F therapy, targeting cancer and autoimmune diseases, to address significant unmet medical needs. Gracell Biotechnologies Inc. is a China-based biotechnology company specializing in developing B-cell maturation antigen (BCMA) therapies for multiple myeloma and B-cell malignancies.

Regional Outlook

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?

The B-cell maturation antigen (BCMA) targeted therapies market consists of revenues earned by entities by providing services such as research and development services, clinical trials management, manufacturing and production services, regulatory consulting and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The B-cell maturation antigen (BCMA) targeted therapies market also includes sales of antibody-drug conjugates (ADCs), BCMA-targeted immunotherapies, and gene therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026?

The b-cell maturation antigen (bcma) targeted therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the b-cell maturation antigen (bcma) targeted therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.